Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 23 | 2024 | 212 | 3.970 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 11 | 2023 | 32 | 2.610 |
Why?
|
| Antitubercular Agents | 16 | 2023 | 90 | 2.280 |
Why?
|
| Tuberculosis | 7 | 2024 | 104 | 1.630 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 11 | 2023 | 60 | 1.330 |
Why?
|
| Microbial Sensitivity Tests | 14 | 2023 | 290 | 1.320 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 7 | 2023 | 11 | 1.050 |
Why?
|
| Latent Tuberculosis | 4 | 2024 | 9 | 0.910 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2022 | 85 | 0.590 |
Why?
|
| Fluoroquinolones | 5 | 2023 | 37 | 0.550 |
Why?
|
| Mutation | 8 | 2020 | 1504 | 0.500 |
Why?
|
| Sequence Analysis, DNA | 8 | 2019 | 274 | 0.480 |
Why?
|
| Bacterial Proteins | 7 | 2023 | 456 | 0.440 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2016 | 40 | 0.440 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2017 | 81 | 0.400 |
Why?
|
| Isoniazid | 5 | 2023 | 30 | 0.390 |
Why?
|
| Air Pollution | 2 | 2019 | 45 | 0.320 |
Why?
|
| Air Pollutants | 2 | 2019 | 70 | 0.320 |
Why?
|
| California | 3 | 2019 | 90 | 0.260 |
Why?
|
| DNA, Bacterial | 5 | 2019 | 172 | 0.250 |
Why?
|
| Humans | 29 | 2024 | 54397 | 0.250 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2022 | 19 | 0.220 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 2 | 0.220 |
Why?
|
| Lung Diseases | 1 | 2023 | 86 | 0.220 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 206 | 0.210 |
Why?
|
| Sputum | 3 | 2016 | 56 | 0.210 |
Why?
|
| Pneumonia | 1 | 2022 | 129 | 0.200 |
Why?
|
| Laboratories | 1 | 2020 | 21 | 0.190 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 922 | 0.190 |
Why?
|
| Residence Characteristics | 2 | 2019 | 166 | 0.190 |
Why?
|
| Trees | 1 | 2019 | 19 | 0.180 |
Why?
|
| Urban Health Services | 1 | 2019 | 23 | 0.180 |
Why?
|
| Health Care Costs | 2 | 2018 | 175 | 0.170 |
Why?
|
| Directly Observed Therapy | 1 | 2018 | 8 | 0.170 |
Why?
|
| Transcriptome | 1 | 2021 | 346 | 0.170 |
Why?
|
| DNA Gyrase | 2 | 2015 | 5 | 0.170 |
Why?
|
| Adult | 9 | 2022 | 14210 | 0.160 |
Why?
|
| Catalase | 2 | 2015 | 74 | 0.160 |
Why?
|
| HIV Infections | 1 | 2022 | 394 | 0.160 |
Why?
|
| Vehicle Emissions | 1 | 2017 | 17 | 0.160 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 26 | 0.140 |
Why?
|
| ROC Curve | 1 | 2017 | 259 | 0.140 |
Why?
|
| Middle Aged | 7 | 2021 | 13083 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2016 | 62 | 0.140 |
Why?
|
| Moldova | 4 | 2018 | 8 | 0.140 |
Why?
|
| South Africa | 4 | 2018 | 20 | 0.140 |
Why?
|
| India | 4 | 2018 | 81 | 0.130 |
Why?
|
| Aged | 5 | 2019 | 10061 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2023 | 2606 | 0.120 |
Why?
|
| Kanamycin | 3 | 2023 | 5 | 0.120 |
Why?
|
| Point Mutation | 1 | 2013 | 92 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1477 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2024 | 195 | 0.110 |
Why?
|
| Male | 8 | 2021 | 27348 | 0.110 |
Why?
|
| Research Design | 1 | 2014 | 375 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 520 | 0.100 |
Why?
|
| Female | 8 | 2021 | 28474 | 0.100 |
Why?
|
| Lyme Disease | 1 | 2011 | 28 | 0.100 |
Why?
|
| Oxidoreductases | 3 | 2015 | 62 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2017 | 1362 | 0.100 |
Why?
|
| Environment | 1 | 2011 | 103 | 0.090 |
Why?
|
| Rifampin | 2 | 2023 | 57 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 825 | 0.090 |
Why?
|
| Genotype | 3 | 2017 | 600 | 0.090 |
Why?
|
| Antigens, Bacterial | 2 | 2024 | 63 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 552 | 0.090 |
Why?
|
| Capreomycin | 2 | 2023 | 3 | 0.080 |
Why?
|
| Amikacin | 2 | 2023 | 19 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 4319 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 2 | 2019 | 291 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 1045 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 3210 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 3431 | 0.070 |
Why?
|
| Child | 4 | 2022 | 7368 | 0.060 |
Why?
|
| Adolescent | 4 | 2018 | 6901 | 0.060 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2024 | 33 | 0.060 |
Why?
|
| Tuberculin Test | 1 | 2023 | 9 | 0.060 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2023 | 8 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1301 | 0.060 |
Why?
|
| Mitochondrial Dynamics | 1 | 2022 | 22 | 0.060 |
Why?
|
| Kenya | 1 | 2022 | 13 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 24 | 0.050 |
Why?
|
| Peptides | 1 | 2024 | 276 | 0.050 |
Why?
|
| Proteome | 1 | 2024 | 178 | 0.050 |
Why?
|
| Tissue Array Analysis | 1 | 2021 | 50 | 0.050 |
Why?
|
| State Medicine | 1 | 2021 | 17 | 0.050 |
Why?
|
| England | 1 | 2021 | 61 | 0.050 |
Why?
|
| Phenotype | 2 | 2014 | 819 | 0.050 |
Why?
|
| Ofloxacin | 1 | 2019 | 10 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 742 | 0.040 |
Why?
|
| Video Recording | 1 | 2018 | 90 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 109 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 697 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1229 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2018 | 133 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 38 | 0.040 |
Why?
|
| Kanamycin Resistance | 1 | 2016 | 1 | 0.040 |
Why?
|
| Molecular Typing | 1 | 2016 | 10 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2016 | 67 | 0.040 |
Why?
|
| Risk | 1 | 2017 | 343 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 430 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2016 | 54 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1141 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2017 | 205 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 86 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 39 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 120 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 58 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 736 | 0.030 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2014 | 25 | 0.030 |
Why?
|
| Philippines | 1 | 2013 | 8 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 122 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 74 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 807 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 719 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2017 | 1547 | 0.030 |
Why?
|
| Acetyltransferases | 1 | 2012 | 23 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2012 | 29 | 0.030 |
Why?
|
| Maryland | 1 | 2011 | 34 | 0.030 |
Why?
|
| United States | 1 | 2022 | 5209 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 5612 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 3937 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1084 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 825 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 4158 | 0.020 |
Why?
|